PubMed

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.

Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H 3rd, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL.

J Hematol Oncol. 2009 May 13;2:20.PMID: 19439093 [PubMed - in process]Related articlesFree article

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A.

Blood. 2009 Jun 25;113(26):6533-40. Epub 2009 Apr 27.PMID: 19398716 [PubMed - indexed for MEDLINE]Related articles

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF.

J Clin Oncol. 2006 Jun 1;24(16):2456-64. Epub 2006 May 1.PMID: 16651647 [PubMed - indexed for MEDLINE]Related articles

Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).

Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C 3rd, Stone RM, Bloomfield CD, Larson RA; Cancer and Leukemia Group.

Cancer. 2009 Jan 1;115(1):84-93.PMID: 19025972 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.

J Clin Oncol. 1995 Jan;13(1):210-21.PMID: 7799022 [PubMed - indexed for MEDLINE]Related articles

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.

Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N.

Cancer. 2008 Oct 1;113(7):1596-604.PMID: 18720364 [PubMed - indexed for MEDLINE]Related articlesFree article

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE.

Blood. 2003 Aug 1;102(3):795-801. Epub 2003 Mar 20.PMID: 12649163 [PubMed - indexed for MEDLINE]Related articlesFree article

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.PMID: 16845641 [PubMed - indexed for MEDLINE]Related articles

Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.

Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V.

Oncology. 2002;62(3):216-22.PMID: 12065868 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.

Ann Oncol. 1995 Feb;6(2):133-40.PMID: 7786821 [PubMed - indexed for MEDLINE]Related articles

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.

Kisicki JC, Fiske K, Lyne A.

Clin Ther. 2007 Sep;29(9):1967-79.PMID: 18035196 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.PMID: 14519631 [PubMed - indexed for MEDLINE]Related articlesFree article

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P.

J Clin Oncol. 2006 Jun 1;24(16):2465-71. Epub 2006 May 1.PMID: 16651646 [PubMed - indexed for MEDLINE]Related articles

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM.

Invest New Drugs. 2008 Feb;26(1):59-65. Epub 2007 Oct 16.PMID: 17938863 [PubMed - indexed for MEDLINE]Related articles

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL.

J Clin Oncol. 2009 Apr 10;27(11):1850-6. Epub 2009 Mar 2.PMID: 19255328 [PubMed - indexed for MEDLINE]Related articles

A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.

Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A.

Cancer Chemother Pharmacol. 2006 Dec;58(6):759-64. Epub 2006 May 23.PMID: 16847673 [PubMed - indexed for MEDLINE]Related articles

Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).

LoRusso PM, Prakash S, Wozniak A, Flaherty L, Zalupski M, Shields A, Sands H, Parchment R, Jasti B.

Invest New Drugs. 2002 Feb;20(1):63-71.PMID: 12003195 [PubMed - indexed for MEDLINE]Related articles

Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.

Stasi R, Pagano A, Terzoli E, Amadori S.

Br J Haematol. 1999 Apr;105(1):141-8.PMID: 10233377 [PubMed - indexed for MEDLINE]Related articles

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R.

Oncologist. 2005 Mar;10(3):176-82. Review.PMID: 15793220 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, Demakos EP, Cornell CJ Jr, Carey RW, Schiffer C, et al.

Leukemia. 1993 May;7 Suppl 1:21-9.PMID: 7683352 [PubMed - indexed for MEDLINE]Related articles